# Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis

> **NCT00956098** · PHASE2 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 81 (—)

## Conditions studied

- Liver Fibrosis
- Liver Cirrhosis

## Interventions

- **DRUG:** oltipraz
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00956098
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 81 (—)
- **Last updated:** 2009-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00956098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00956098, "Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00956098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*